Sciessent and Compounding Solutions Partner to Create Antimicrobial-Embedded Materials for Medical-Device Manufacturers

Companies Integrate Antimicrobial Solutions into Polymers to Provide Ready-to-Use Materials and Concentrates

WAKEFIELD, Mass. (PRWEB) March 16, 2015 -- Sciessent, the leading provider of antimicrobial solutions, today announced its partnership with Compounding Solutions, a leader in the production of specialty compounds for the medical-device industry. Compounding Solutions will integrate Sciessent's Agion® technology into polymers to provide custom antimicrobial compounds that can be easily leveraged in existing manufacturing processes of medical devices to impart antimicrobial properties in the finished products.

With healthcare-associated infections (HAIs) impacting one in 25 patients in the United States alone, med-device manufacturers are increasingly looking for antimicrobial-infused materials to leverage in product design, development and production. Through the Sciessent and Compounding Solutions partnership, med-device companies have custom antimicrobial-embedded materials at their disposal for the faster, more efficient manufacturing of antimicrobial medical devices.

"The combination of Sciessent's decades of expertise in embedded antimicrobials and Compounding Solutions' deep knowledge of materials for the med-device industry, will ensure that we efficiently develop antimicrobial solutions for healthcare partners for years to come," said Lise Moloney, director of business development, healthcare, Sciessent.

"I am excited about this strategic alliance with Sciessent and its Agion antimicrobial technology," said Scott Neal, owner and general manager, Compounding Solutions. "We have been working closely with Sciessent for almost 10 years and have developed a great relationship during that time. This will only improve on that and both companies will surely benefit."

About Compounding Solutions
Compounding Solutions is an industry leader in producing quality specialty compounds for the medical device industry, a leader in technological advancement, and has a wealth of knowledge in materials selection and development. The company was started in 1999 with the purpose of becoming the leading compounder for the medical device industry. Since then, the company has completed two building expansions to get to the current facility of 60,000 sq. ft. The current facility includes eleven compounding lines, including two new additions coming in 2015, ranging from 18mm to 50mm, warehouse and office space, as well as a state of the art 7,000 sq. ft., controlled environment white room for medical compounding. For more information, visit the company website at www.compoundingsolutions.net

About Sciessent LLC
Sciessent is a leading provider of customized antimicrobial solutions that enhance the value of customers' products. Agion antimicrobial solutions from Sciessent have been incorporated into a wide range of healthcare, industrial and consumer applications, including medical devices such as central-venous catheters and IV access ports, drinking-water applications like water filters and ice-making equipment, and textiles and apparel. The company's brands include Agion, Agion Active and Sciessent Lava and are based on naturally occurring elements. Sciessent customers include leading international brands including Vygon, Medegen, Scotsman, Everpure, Follett, Honeywell, UnderArmour, Adidas, Reebok and Skechers.

The Agion® Antimicrobial is presently registered by the United States Environmental Protection Agency as a preservative and bacteriostatic agent for use in treated articles under 40 CFR 152.25a. The information presented herein is not intended to support or endorse public health claims for treated articles. The Agion Antimicrobial is also used in medical devices under the Food and Drug Administration in the US; those medical device claims are based on safety and efficacy testing and are limited to those approved by FDA. In the EU, the Agion Antimicrobial is used in medical devices under the Medical Device Directive: those medical device claims are based on safety and efficacy testing and are limited to those approved by the designated Competent Authorities and/or Notified Bodies.

# # #

Media Contact
Megan Coyle
KDV Communications, Inc.
(P): 347.603.5096
meg(at)kdvcommunications(dot)com

Contact Information
Megan Coyle
Sciessent
http://www.tvsquared.com
+1 347-603-5096

Online Web 2.0 Version
You can read the online version of this press release here.